Incyte secures EU approval for Povofortay (povorcitinib), the first once-daily oral treatment for eligible adults with moderate to severe hidradenitis suppurativa.
Written By: Faiza, PharmD
Reviewed By: Pharmacally Editorial Team
On November 16, 2026, Incyte announced that the European Commission (EC) had approved Povofortay® (povorcitinib) 45 mg and 75 mg for adults with active moderate to severe hidradenitis suppurativa (HS) who have responded inadequately to, are intolerant of, or have contraindications to anti-tumor necrosis factor (TNF) therapy. According to the company, Povofortay is the first and only once-daily oral treatment approved in the European Union for this patient population.
The approval provides a new oral treatment option for patients with HS, a chronic inflammatory skin condition characterized by painful nodules, abscesses and draining tunnels that can lead to scarring and irreversible tissue damage.
Phase 3 STOP-HS1 and STOP-HS2 Trial Design
The approval is based on two pivotal Phase 3 trials, STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836). The randomized, double-blind, placebo-controlled studies enrolled 608 and 619 patients, respectively, with moderate to severe HS.
Participants were randomized in a 2:2:1:1 ratio to receive once-daily povorcitinib 45 mg, povorcitinib 75 mg, or placebo. The initial placebo-controlled period lasted 12 weeks, followed by a 42-week extension. At Week 12, patients initially assigned to placebo crossed over to either povorcitinib dose, while those receiving active treatment continued their assigned regimens.
The primary endpoint was Hidradenitis Suppurativa Clinical Response (HiSCR50), defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count without an increase in abscess or draining tunnel count.
Both Studies Met the Primary Endpoint at Week 12
Both trials met their primary endpoint at Week 12 for both povorcitinib doses.
In STOP-HS1, HiSCR50 was achieved by 40% of patients receiving 45 mg and 41% receiving 75 mg, compared with 30% in the placebo group. In STOP-HS2, response rates were 42% with both doses, compared with 29% with placebo.
The differences were statistically significant across both doses and studies. In STOP-HS1, the odds ratios were 1.6 for both doses (P=0.0240 and P=0.0214, respectively). In STOP-HS2, the odds ratios were 1.8 for 45 mg (P=0.0035) and 1.9 for 75 mg (P=0.0033).
These findings establish the efficacy of both doses against placebo during the controlled treatment period. The company also reported consistent efficacy in patients previously treated with anti-TNF therapy, supporting the population included in the European indication.
Clinical Responses Sustained Through Week 54
During the 54-week treatment period, HiSCR50 response rates reached up to 71.4% across the studies. Higher response thresholds were also observed, with up to 57% of participants achieving HiSCR75 and up to 29% achieving HiSCR100.
At Week 54, clinically meaningful improvements were reported in skin pain (40.5–46.8%), fatigue (49.0–58.0%), skin condition-related quality of life (59.4–64.7%) and HS-specific quality of life (33.7–40.2%).
The findings suggest that clinical improvements extended beyond inflammatory lesion reduction to symptoms and patient-reported outcomes. However, these longer-term results require careful interpretation because the placebo groups crossed over to active treatment after Week 12. Consequently, Week 54 findings do not represent continued placebo-controlled comparisons.
Safety Profile Through 54 Weeks
Povorcitinib demonstrated a safety profile consistent with previously reported findings, with no new or unexpected safety signals identified through Week 54.
The most frequently reported treatment-emergent adverse events included acne, nasopharyngitis and upper respiratory tract infections. Across both studies, acne occurred in 17% of patients receiving 45 mg and 20% receiving 75 mg, while nasopharyngitis was reported in 10% and 12%, respectively. Upper respiratory tract infections occurred in 11% and 10%.
Serious adverse events occurred in approximately 5% and 6% of patients receiving the 45 mg and 75 mg doses, respectively, through Week 54. One death of undetermined etiology was reported during the extension period and was considered unrelated to treatment by the investigator. Herpes zoster and laboratory abnormalities, including increased creatine phosphokinase, were also monitored during the trials.
As a selective Janus kinase 1 (JAK1) inhibitor, povorcitinib requires appropriate monitoring for infections, laboratory abnormalities and other relevant risks associated with JAK inhibitor therapy, in accordance with its approved product information.
Regulatory Status
The European indication is restricted to adults with active moderate to severe HS who have responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy. Treatment should be initiated and supervised by physicians experienced in diagnosing and managing HS.
In the United States, the Food and Drug Administration (FDA) is reviewing Incyte’s New Drug Application (NDA) for povorcitinib in moderate to severe HS. The company anticipates potential US approval and launch in the first quarter of 2027, subject to regulatory review.
Clinical Implications
The European approval advances Incyte’s dermatology portfolio and introduces an oral JAK1-targeted option for patients requiring treatment after inadequate response or intolerance to anti-TNF therapy. Nevertheless, the relatively short placebo-controlled period, absence of direct comparisons with approved biologics and limited follow-up beyond 54 weeks leave important questions regarding comparative effectiveness and long-term safety. The trials also do not establish whether treatment prevents irreversible tissue damage or maintains benefits after discontinuation.
Overall, the STOP-HS1 and STOP-HS2 findings support the European approval of povorcitinib, demonstrating statistically significant improvements in HiSCR50 at Week 12 and sustained clinical responses during longer-term treatment. Further real-world evidence and extended safety follow-up will help establish its position in the HS treatment landscape.
References
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa, Incyte, 16 November 2026
Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib for hidradenitis suppurativa: The randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 Phase 3 trials. Nature Medicine. Published July 23, 2026. https://doi.org/10.1038/s41591-026-04534-z
European Medicines Agency. Povofortay (povorcitinib): Summary of positive opinion. September 17, 2026.
STOP-HS1 (NCT05620823) https://clinicaltrials.gov/study/NCT05620823
STOP-HS2 (NCT05620836) https://clinicaltrials.gov/study/NCT05620836
About the Writer
Faiza (Linkedin) is a Healthcare Writer at Pharmacally and a PharmD professional from St. Peter’s Institute of Pharmaceutical Sciences, Kakatiya University. she has academic and clinical interests in clinical pharmacy, pharmacovigilance and patient care. Her research focuses on serum biomarkers in acute pancreatitis and medication adherence. She is interested in clinical research, medical writing and evidence-based healthcare communication.
